Eli Lilly to Acquire Psychedelic Drugmaker AtaiBeckley for $2.8 Billion

Eli Lilly has announced its intention to acquire AtaiBeckley, a psychedelic drugmaker, in a deal valued at $2.8 billion, signaling a significant move into the emerging field of psychedelic therapeutics.